Companies /Healthcare
Danaher Corp
NYSE: DHR Diagnostics & Research
$219.14
▲ $1.68 (+0.77%) today
Markets open · 10:55am ET

Danaher (DHR) Q3 2025 Earnings

Reported Oct 20, 2025, 5:39pm ET · SEC source
$1.89
Beat +9.78%
EPS · est. $1.72
$6.1B
Beat +0.92%
Revenue · est. $6.0B
+8.0%
Beating market
DHR vs S&P since report
4 quarters
Consecutive EPS beats

How Did DHR Stock React to Q3 2025 Earnings?

% change · around the report
0+5%+10%Oct 20Oct 21report 5:39pm ETearnings−0.2%+6.5%
0+5%+10%Oct 20Oct 21earnings−0.2%+6.5%
DHR +6.5%S&P 500 −0.2%
0+5%+10%Oct 20Oct 21report 5:39pm ETearnings−0.3%+6.5%
0+5%+10%Oct 20Oct 21earnings−0.3%+6.5%
DHR +6.5%NASDAQ −0.3%
0+4%+8%Oct 20Oct 28report 5:39pm ETearnings+2.2%+4.5%
0+4%+8%Oct 20Oct 28earnings+2.2%+4.5%
DHR +4.5%S&P 500 +2.2%
0+4%+8%Oct 20Oct 28report 5:39pm ETearnings+3.5%+4.5%
0+4%+8%Oct 20Oct 28earnings+3.5%+4.5%
DHR +4.5%NASDAQ +3.5%
−0.32%
Day of report
+5.94%
Next session
+6.06%
One week
+6.73%
30 days

S&P 500 over the same 30 days: −1.29%.

Did DHR Beat Earnings? Q3 2025 Results

Yes. Danaher reported Q3 2025 earnings of $1.89 a share on Oct 20, 2025, beating the $1.72 consensus estimate by 9.8%. Revenue was $6.1B against a $6.0B estimate.

Danaher delivered a strong third quarter for 2025, with both earnings and revenue clearing consensus estimates as the life sciences and diagnostics company demonstrated broadening momentum across its portfolio. Non-GAAP adjusted diluted EPS came in at $1.89, beating the $1.72 consensus by 9.78%, while revenue of $6.05 billion edged past the $6.00 billion estimate and grew 4.4% year-over-year. The standout driver was the Biotechnology segment, which posted 9.0% total sales growth fueled by continued strength in bioprocessing, helping offset a modest 1.0% core revenue decline in Life Sciences. Operating cash flow climbed to $1.66 billion from $1.51 billion a year earlier, reflecting solid execution across the business. Looking ahead, management maintained its full-year adjusted diluted EPS guidance of $7.70 to $7.80, with non-GAAP core revenue expected to grow low-single digits, while fourth-quarter guidance points to Biotechnology core growth of approximately 5% and a roughly 2.5% currency tailwind supporting reported sales.

Key Takeaways
  • Continued momentum in bioprocessing business
  • Better-than-anticipated respiratory revenue at Cepheid
  • DBS-driven execution and productivity gains
  • Favorable currency exchange rates providing 1.5% sales tailwind

“We are encouraged by our third quarter results. DBS-driven execution paired with continued momentum in our bioprocessing business and better-than-anticipated respiratory revenue at Cepheid enabled us to exceed our revenue, earnings and cash flow expectations.”

Danaher CEO, on the earnings call

What Was Danaher's Outlook in Q3 2025?

For full year 2025, Danaher is maintaining its adjusted diluted net earnings per common share guidance range of $7.70 to $7.80, with non-GAAP core revenue expected to grow low-single digits year-over-year. For Q4 2025, the company expects Biotechnology core sales growth of approximately 5%, Life Sciences to decline low-single digits, and Diagnostics to be flat, resulting in overall low-single digit core sales growth. Currency exchange rates are expected to increase Q4 sales by approximately 2.5%. Q4 assumptions include corporate expense of approximately $85 million, net interest expense of approximately $50 million, and an effective tax rate of approximately 17%.

DHR YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$2.0B$4.0B$6.0B$5.8B$6.1BRevenue$3.4B$3.5BGross Profit$958.0M$1.2BOperating Income$818.0M$908.0MNet Income
$0$2.0B$4.0B$6.0BRevenueGross ProfitOperating IncomeNet Income
DHR income statement, Q3 2025 versus Q3 2024
Metric Q3 2025 Q3 2024 Year over year
Revenue $6.1B $5.8B +4.4%
Gross Profit $3.5B $3.4B +3.6%
Operating Income $1.2B $958.0M +20.5%
Net Income $908.0M $818.0M +11.0%

DHR Revenue by Segment

Diagnostics
Life Sciences
Biotechnology

Figures from SEC filings and company reports. Not investment advice.